Biogen Lupus Research | New Treatments in Development
New Hope in Lupus Research: Biogen’s Promising Treatments
Biogen, a company known for its work in autoimmune diseases, is developing two new medicines for lupus: litifilimaband dapirolizumab pegol.
Both medicines are in late-stage clinical trials, and early results show they may help reduce lupus activity and improve symptoms. What makes these treatments exciting is that they work in new ways compared to current options, offering hope for better outcomes and fewer side effects.
If successful, these medicines could expand the limited choices available to people living with lupus.
Key Findings
-
Biogen is developing two new lupus medicines: litifilimab and dapirolizumab pegol.
-
Both medicines are in late-stage clinical trials (Phase 3).
-
Early results suggest they may reduce lupus activity and improve symptoms.
-
These medicines use new mechanisms compared to existing options.
Implications
For people living with lupus: If approved, these medicines could expand treatment options and offer alternatives with different safety and effectiveness profiles.
For healthcare professionals: These therapies highlight promising new pathways in lupus care, potentially reshaping future treatment strategies.
Want to learn more about current lupus treatments? Visit our Understanding Your Lupus Care: Management and Treatment page on for an overview of medicines most commonly prescribed, working with your healthcare team, and other potential therapies.